- Home
- IMMX vs ARQQ Comparison
IMMX vs ARQQ Comparison
Compare IMMX & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMMX | ARQQ |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.2M | 399.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMMX | ARQQ |
|---|---|---|
| Price | $5.31 | $21.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 1.5M | 363.4K |
| Earning Date | 11-07-2025 | 12-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $530,000.00 |
| Revenue This Year | N/A | $1,054.72 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.34 | $11.00 |
| 52 Week High | $7.73 | $62.00 |
Technical Indicators
Market Signals| Indicator | IMMX | ARQQ |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 36.09 |
| Support Level | $5.46 | $21.63 |
| Resistance Level | $6.09 | $28.09 |
| Average True Range (ATR) | 0.58 | 2.11 |
| MACD | -0.17 | -0.17 |
| Stochastic Oscillator | 2.02 | 3.23 |
Price Performance
Historical ComparisonAbout IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.